Giaccone G, Donadio M, Bonardi G M, Testore F, Calciati A
Division of Medical Oncology, Ospedale S. Giovanni, Antica Sede, Torino, Italy.
Eur J Cancer Clin Oncol. 1988 Apr;24(4):629-31. doi: 10.1016/0277-5379(88)90291-x.
Despite good results of chemotherapy in small cell lung cancer (SCLC), occurrence of brain metastases is frequent and unaffected by commonly employed antineoplastic drugs, mainly because they do not cross the blood-brain barrier. We treated eight patients with SCLC and cerebral metastases with VM26 at 120 mg/m2 given on days 1, 3 and 5 and repeated every 3 weeks. Two patients achieved complete response and one had partial response. Mean response duration was 8.2 months and survival was more than 9 months in responding patients. Toxicity was manageable. VM26 is an active drug in SCLC with brain metastases.
